COCP — Cocrystal Pharma Share News
0.000.00%
Last trade - 00:00Brief: Fred Hassan Reports Passive Stake Of 10% In Cocrystal Pharma Inc As Of April 4, 2023 - SEC Filing
Brief: Cocrystal Pharma Completes $4 Mln Private Placement Priced At-The-Market Under Nasdaq Rules
Brief: Cocrystal Pharma Reports 2022 Financial Results
Cocrystal Pharma Inc reports results for the quarter ended in December - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Cocrystal Pharma Reports Mostly Positive Results From A Phase 1 Study With Its Oral Antiviral Cc-42344 For The Treatment Of Pandemic And Seasonal Influenza A
Brief: Cocrystal Pharma Inc Affirms Plans To Report Topline Phase 1 Results In 2022 Andto Initiatephase 2A Influenza Human Challenge Trial In 2023
Cocrystal Pharma gains on influenza drug trial data
Brief: Cocrystal Pharma Announces Favorable Safety Data From The Phase 1 Study With Oral Antiviral Cc-42344 That Treats Pandemic, Seasonal Influenza A
Brief: Cocrystal Pharma Reports Q3 Financial Results, Provides Updates On Its Antiviral Development Programs
Cocrystal Pharma Inc reports results for the quarter ended in September - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Enrollment Completed In Phase 1 Influenza A Study With Cocrystal Pharma’S Oral Antiviral Candidate Cc-42344
Brief: Cocrystal Pharma To Present Cc-42344 Phase 1 Influenza A Data At The World Antiviral Congress 2022
U.S. STOCKS ON THE MOVE-Inhibrx, big banks, Ferroglobe
U.S. STOCKS ON THE MOVE-Illumina, energy firms, Cue Biopharma
Cocrystal Pharma down on 1-for-12 reverse stock split plan
Brief: Cocrystal Pharma Announces A 1-For-12 Reverse Stock Split
Cocrystal Pharma Inc reports results for the quarter ended in June - Earnings Summary